Cytokinetics CEO sells 7,500 company shares
CYTOKINETICS INC President & CEO Robert I. Blum reported an open-market sale of 7,500 shares of Common Stock at $59.62 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
CYTOKINETICS INC President & CEO Robert I. Blum reported an open-market sale of 7,500 shares of Common Stock at $59.62 per share. The transaction took place on April 29, 2026 and is classified as a non-derivative sale.
After this sale, Blum directly holds 407,830 shares of Cytokinetics common stock. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares are held indirectly by The Brittany Blum 2003 Irrevocable Trust.
Insider Trade Summary 10b5-1
Net Seller: 7,500 shares
Net Sell
3 txns
Insider
Blum Robert I
Role
President & CEO
Sold
7,500 shs ($447K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 7,500 | $59.62 | $447K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 407,830 shares (Direct);
Common Stock — 2,083 shares (Indirect, by Trust 1);
Common Stock — 2,083 shares (Indirect, by Trust 2)
Footnotes (2)
- F1. Shares held by The Bridget Blum 2003 Irrevocable Trust.
- F2. Shares held by The Brittany Blum 2003 Irrevocable Trust.
Key Figures
Shares sold: 7,500 shares
Sale price per share: $59.62 per share
Direct holdings after sale: 407,830 shares
+2 more
5 metrics
Shares sold
7,500 shares
Open-market sale of Common Stock on April 29, 2026
Sale price per share
$59.62 per share
Price for the 7,500-share open-market sale
Direct holdings after sale
407,830 shares
Common Stock directly owned by Robert I. Blum after transaction
Bridget Blum Trust holdings
2,083 shares
Common Stock held by The Bridget Blum 2003 Irrevocable Trust
Brittany Blum Trust holdings
2,083 shares
Common Stock held by The Brittany Blum 2003 Irrevocable Trust
Key Terms
open-market sale, non-derivative, indirect ownership, Irrevocable Trust, +1 more
5 terms
open-market sale financial
"Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
non-derivative financial
"transaction_type: "non-derivative" for the 7,500-share sale"
indirect ownership financial
"ownership_type: "indirect" with nature_of_ownership by Trust 1 and Trust 2"
Irrevocable Trust financial
"Shares held by The Bridget Blum 2003 Irrevocable Trust."
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CYTOKINETICS (CYTK) report for Robert I. Blum?
CYTOKINETICS reported that President & CEO Robert I. Blum completed an open-market sale of 7,500 shares of Common Stock. The transaction was a non-derivative sale executed on April 29, 2026, and is disclosed as a standard Form 4 insider trading report.
What indirect holdings in CYTOKINETICS (CYTK) are linked to Robert I. Blum?
Indirect holdings include 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust. These positions are reported as indirect ownership entries associated with Robert I. Blum in the Form 4 filing.
What type of transaction code is used for the CYTK CEO’s insider sale?
The insider sale is reported with transaction code “S,” which identifies a sale in an open market or private transaction. The filing classifies this as a non-derivative transaction in Cytokinetics Common Stock for President & CEO Robert I. Blum.
Does the CYTOKINETICS (CYTK) Form 4 show any option exercises or derivative trades?
The Form 4 does not report any derivative transactions or option exercises for this event. It lists a single non-derivative open-market sale of 7,500 shares and separate holding entries for indirect shares owned through two irrevocable trusts.
AI-generated analysis. How Rhea-AI works. Not financial advice.
